Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1611-1621

  Martín, Rebeca ^a   Chain, Florian ^a   Miquel, Sylvie ^a   Natividad, Jane M ^b   Sokol, Harry ^a,c,d   Verdu, Elena F ^b   Langella, Philippe ^a   Bermúdez Humarán, Luis G ^a  

^a UMR1319 MICALIS   (France)

^b MCMASTER UNIVERSITY   (Canada)

^c HÔPITAL SAINT ANTOINE   (France)

^d INSERM   (France)

Author keywords

Genetically engineered bacteria; Gut hyperpermeability; IBS; IL 10; Lactococcis lactis; Probiotic

Indexed keywords

CLAUDIN 4; INTERLEUKIN 10; OCCLUDIN; PROTEIN ZO1; SEROTONIN; TIGHT JUNCTION PROTEIN; UVOMORULIN; CYTOKINE; IMMUNOLOGIC FACTOR; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CELL POPULATION; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; IMMUNOSTIMULATION; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; LACTOCOCCUS LACTIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; ANIMAL; BIOLOGICAL THERAPY; C57BL MOUSE; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL THERAPY; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERLEUKIN-10; LACTOCOCCUS LACTIS; MALE; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; SEROTONIN; SPLEEN; TREATMENT OUTCOME;

EID: 84899876481     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28549     Document Type: Article

References (43)

1. Collins SM. Is the irritable gut an inflamed gut? Scand J Gastroenterol Suppl 1992; 192:102-5; PMID:1439559; http://dx.doi.org/10.3109/00365529209095988
2. Khan S, Chang L. Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol 2010; 7:565-81; PMID:20890316; http://dx.doi.org/10.1038/nrgastro.2010. 137
3. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011; 46:421-31; PMID:21331765; http://dx.doi.org/10.1007/s00535-011-0379-9
4. Ohman L, Simrén M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007; 39:201-15; PMID:17267314; http://dx.doi.org/10.1016/j.dld.2006.10.014
5. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM; WEL Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20:1317-22; PMID:15606393; http://dx.doi.org/10. 1111/j.1365-2036.2004.02284.x
6. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010; 1:97-105; PMID:21607147; http://dx.doi.org/10. 4291/wjgp.v1.i3.97
7. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2013; In press; PMID:23878165
8. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107:1474-82; PMID:22929759; http://dx.doi.org/10.1038/ajg.2012.260
9. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002; 97:389-96; PMID:11866278; http://dx.doi.org/10.1111/j.1572- 0241.2002.05475.x
10. Bermúdez-Humarán LG, Aubry C, Motta JP, Deraison C, Steidler L, Vergnolle N, Chatel JM, Langella P. Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol 2013; 16:278-83; PMID:23850097; http://dx.doi.org/10.1016/j.mib.2013.06.002
11. Seegers JF. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 2002; 20:508-15; PMID:12443872; http://dx.doi.org/10.1016/S0167-7799(02)02075-9
12. Lee SF, Halperin SA, Salloum DF, MacMillan A, Morris A. Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein. Infect Immun 2003; 71:2272-5; PMID:12654855; http://dx.doi.org/10.1128/IAI.71.4.2272-2275.2003
13. Cortes-Perez NG, Bermúdez-Humarán LG, Le Loir Y, Rodriguez-Padilla C, Gruss A, Saucedo-Cárdenas O, Langella P, Montes-de-Oca-Luna R. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol Lett 2003; 229:37-42; PMID:14659540; http://dx.doi.org/10.1016/S0378-1097(03)00778-X
14. Bermúdez-Humarán LG, Langella P, Cortes-Perez NG, Gruss A, Tamez-Guerra RS, Oliveira SC, Saucedo-Cardenas O, Montes de Oca-Luna R, Le Loir Y. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003; 71:1887-96; PMID:12654805; http://dx.doi.org/10.1128/IAI.71.4.1887-1896. 2003
15. Bermúdez-Humarán LG, Cortes-Perez NG, Le Loir Y, Alcocer-González JM, Tamez-Guerra RS, de Oca-Luna RM, Langella P. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. J Med Microbiol 2004; 53:427-33; PMID:15096553; http://dx.doi.org/10.1099/jmm.0.05472-0
16. Grangette C, Müller-Alouf H, Goudercourt D, Geoffroy MC, Turneer M, Mercenier A. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun 2001; 69:1547-53; PMID:11179325; http://dx.doi.org/10.1128/IAI.69.3.1547-1553. 2001
17. Krüger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, et al. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 2002; 20:702-6; PMID:12089555; http://dx.doi.org/10.1038/nbt0702-702
18. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol 1997; 15:653-7; PMID:9219268; http://dx.doi.org/10.1038/nbt0797-653
19. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21:785-9; PMID:12808464; http://dx.doi.org/10.1038/nbt840
20. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289:1352-5; PMID:10958782; http://dx.doi.org/10. 1126/science.289.5483.1352
21. Schotte L, Steidler L, Vandekerckhove J, Remaut E. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol 2000; 27:761-5; PMID:11118583; http://dx.doi.org/10.1016/S0141-0229(00) 00297-0
22. Benbouziane B, Ribelles P, Aubry C, Martin R, Kharrat P, Riazi A, Langella P, Bermúdez-Humarán LG. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol 2013; 168:120-9; PMID:23664884; http://dx.doi.org/10.1016/j.jbiotec.2013.04.019
23. Martín R, Chain F, Miquel S, Lu J, Gratadoux JJ, Sokol H, Verdu EF, Bercik P, Bermúdez-Humarán LG, Langella P. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis 2014; 20:417-30; PMID:24418903; http://dx.doi.org/10.1097/01.MIB.0000440815.76627.64
24. Martín R, Miquel S, Ulmer J, Kechaou N, Langella P, Bermúdez-Humarán LG. Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. Microb Cell Fact 2013; 12:71; PMID:23876056; http://dx.doi.org/10.1186/1475-2859-12-71
25. Motta JP, Bermúdez-Humarán LG, Deraison C, Martin L, Rolland C, Rousset P, Boue J, Dietrich G, Chapman K, Kharrat P, et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 2012; 4:ra144; PMID:23115353; http://dx.doi.org/10.1126/scitranslmed.3004212
26. Galipeau HJ, Wiepjes M, Motta JP, Schulz JD, Jury J, Natividad JM, Pinto-Sanchez I, Sinclair D, Rousset P, Martin-Rosique R, et al. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders. Am J Gastroenterol 2014; (Forthcoming); PMID:24710505; http://dx.doi.org/10.1038/ajg. 2014.48
27. Foligne B, Dessein R, Marceau M, Poiret S, Chamaillard M, Pot B, Simonet M, Daniel C. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 2007; 133:862-74; PMID:17678918; http://dx.doi.org/10.1053/j.gastro.2007.06.018
28. Smelt MJ, de Haan BJ, Bron PA, van Swam I, Meijerink M, Wells JM, Faas MM, de Vos P. L. plantarum, L. salivarius, and L. lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner. PLoS One 2012; 7:e47244; PMID:23056616; http://dx.doi.org/10.1371/journal.pone. 0047244
29. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005; 175:7297-302; PMID:16301635; http://dx.doi.org/10.4049/ jimmunol.175.11.7297
30. Shashidharamurthy R, Machiah D, Aitken JD, Putty K, Srinivasan G, Chassaing B, Parkos CA, Selvaraj P, Vijay-Kumar M. Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice. Arthritis Rheum 2013; 65:1064-73; PMID:23280250; http://dx.doi.org/10. 1002/art.37840
31. Vijay-Kumar M, Wu H, Jones R, Grant G, Babbin B, King TP, Kelly D, Gewirtz AT, Neish AS. Flagellin suppresses epithelial apoptosis and limits disease during enteric infection. Am J Pathol 2006; 169:1686-700; PMID:17071592; http://dx.doi.org/10.2353/ajpath.2006.060345
32. Miyauchi EMH, Morita H, Tanabe S. Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase in vivo. J Dairy Sci 2009; 92:2400-8; PMID:19447972; http://dx.doi.org/10.3168/jds.2008-1698
33. Mennigen RNK, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, Bruewer M. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296:G1140-9; PMID:19221015; http://dx.doi.org/10.1152/ajpgi.90534.2008
34. Coates MD, Johnson AC, Greenwood-Van Meerveld B, Mawe GM. Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil 2006; 18:464-71; PMID:16700726; http://dx.doi.org/10.1111/j.1365-2982.2006.00792.x
35. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 2010; 161:19-27; PMID:20408856
36. Bertrand PP, Barajas-Espinosa A, Neshat S, Bertrand RL, Lomax AE. Analysis of real-time serotonin (5-HT) availability during experimental colitis in mouse. Am J Physiol Gastrointest Liver Physiol 2010; 298:G446-55; PMID:20019165; http://dx.doi.org/10.1152/ajpgi.00318.2009
37. Qin HY, Xiao HT, Wu JC, Berman BM, Sung JJ, Bian ZX. Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats. World J Gastroenterol 2012; 18:2481-92; PMID:22654445; http://dx.doi.org/10.3748/wjg.v18.i20.2481
38. Wallace JL, Le T, Carter L, Appleyard CB, Beck PL. Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Toxicol Methods 1995; 33:237-9; PMID:8527832; http://dx.doi.org/10.1016/1056- 8719(95)00001-X
39. Appleyard CB, Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 1995; 269:G119-25; PMID:7631788
40. Qiu BS, Vallance BA, Blennerhassett PA, Collins SM. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat Med 1999; 5:1178-82; PMID:10502822; http://dx.doi.org/10.1038/8328
41. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238-49; PMID:8350599
42. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78:206-9; PMID:6276474; http://dx.doi.org/10.1111/1523- 1747.ep12506462
43. Tambuwala MM, Cummins EP, Lenihan CR, Kiss J, Stauch M, Scholz CC, Fraisl P, Lasitschka F, Mollenhauer M, Saunders SP, et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 2010; 139:2093-101; PMID:20600011; http://dx.doi.org/10.1053/j.gastro.2010.06.068